Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liss, H. P.
Right arrow Articles by Bernstein, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liss, H. P.
Right arrow Articles by Bernstein, J.

Chest, Vol 93, 1239-1241, Copyright © 1988 by American College of Chest Physicians

ARTICLES

Ribavirin aerosol in the elderly

HP Liss and J Bernstein
Department of Medicine, Wright State University School of Medicine, Dayton, OH.

Ribavirin aerosol is effective in treating respiratory syncytial virus and influenzal infections in children and young adults. It has not been studied in elderly patients. We evaluated the safety of ribavirin aerosol in eight elderly volunteers at high risk for influenza. Their mean age was 64 years; seven subjects had chronic obstructive pulmonary disease (COPD). Subjects received ribavirin aerosol for two or six hours with six hours between treatments. Regimens were continued for 96 hours. The drug was well tolerated. Subjects receiving ribavirin for 2 hours demonstrated a significant decrease in their forced expiratory volume in one second, peak expiratory flow rate and flow over the middle 50 percent of the forced vital capacity. These changes were small and the subjects' symptoms remained stable. Subjects receiving ribavirin for 6 hours had no significant changes in pulmonary function. We conclude that ribavirin aerosol is safe in elderly patients with underlying COPD.


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
A. R. Falsey and E. E. Walsh
Respiratory Syncytial Virus Infection in Adults
Clin. Microbiol. Rev., July 1, 2000; 13(3): 371 - 384.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American College of Chest Physicians.